Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of MAP2K1/MAP2K2 polyclonal antibody
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Chicken,Human,Mouse,Rat |
| Host species | Rabbit |
| Applications | IP,ELISA,WB-Ce |
More info about MAP2K1/MAP2K2 polyclonal antibody
| Brand: | Abnova |
| Reference: | PAB12706 |
| Product name: | MAP2K1/MAP2K2 polyclonal antibody |
| Product description: | Rabbit polyclonal antibody raised against synthetic peptide of MAP2K1/MAP2K2. |
| Gene id: | 5604|5605 |
| Gene name: | MAP2K1 |
| Gene alias: | MAPKK1|MEK1|MKK1|PRKMK1 |
| Gene description: | mitogen-activated protein kinase kinase 1 |
| Immunogen: | A synthetic peptide corresponding to internal domain of human MAP2K1/MAP2K2. |
| Form: | Liquid |
| Recommend dilutions: | Western Blot (0.1-1 ug/mL) ELISA (0.01-0.1 ug/mL) Immunoprecipitation (2-5 ug/mL) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In TBS, pH 7.2 (BSA, 10% Proclin300) |
| Storage instruction: | Store at 4°C. For long term storage store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Quality control testing: | Antibody Reactive Against Synthetic Peptide. |
| Product type: | Primary antibodies |
| Host species: | Rabbit |
| Antigen species / target species: | Human |
| Specificity: | This antibody recognizes ~44, 45 KDa of human MAP2K1/MAP2K2. |
| Reactivity: | Chicken,Human,Mouse,Rat |
| Application image: |  |
| Application image note: | The whole cell lysates derived from NIH/3T3 were immunoblotted by MAP2K1/MAP2K2 polyclonal antibody (Cat # PAB12706) at 1 : 1000. |
| Applications: | IP,ELISA,WB-Ce |
| Shipping condition: | Dry Ice |
| Publications: | Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Cancer Res. 2004 Oct 1;64(19):7117-26. |